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ABSTRACT
Purpose and scope The aim of this Position
Statement is to provide recommendations for Canadian
medical geneticists, clinical laboratory geneticists, genetic
counsellors and other physicians regarding the use of
genome-wide sequencing of germline DNA in the
context of clinical genetic diagnosis. This statement has
been developed to facilitate the clinical translation and
development of best practices for clinical genome-wide
sequencing for genetic diagnosis of monogenic diseases
in Canada; it does not address the clinical application of
this technology in other ﬁelds such as molecular
investigation of cancer or for population screening of
healthy individuals.
Methods of statement development Two
multidisciplinary groups consisting of medical geneticists,
clinical laboratory geneticists, genetic counsellors,
ethicists, lawyers and genetic researchers were
assembled to review existing literature and guidelines on
genome-wide sequencing for clinical genetic diagnosis in
the context of monogenic diseases, and to make
recommendations relevant to the Canadian context.
The statement was circulated for comment to the
Canadian College of Medical Geneticists (CCMG)
membership-at-large and, following incorporation
of feedback, approved by the CCMG Board of
Directors. The CCMG is a Canadian organisation
responsible for certifying medical geneticists and clinical
laboratory geneticists, and for establishing professional
and ethical standards for clinical genetics services in
Canada.
Results and conclusions Recommendations include
(1) clinical genome-wide sequencing is an appropriate
approach in the diagnostic assessment of a patient for
whom there is suspicion of a signiﬁcant monogenic
disease that is associated with a high degree of genetic
heterogeneity, or where speciﬁc genetic tests have failed
to provide a diagnosis; (2) until the beneﬁts of reporting
incidental ﬁndings are established, we do not endorse
the intentional clinical analysis of disease-associated
genes other than those linked to the primary indication;
and (3) clinicians should provide genetic counselling and

obtain informed consent prior to undertaking clinical
genome-wide sequencing. Counselling should include
discussion of the limitations of testing, likelihood and
implications of diagnosis and incidental ﬁndings, and the
potential need for further analysis to facilitate clinical
interpretation, including studies performed in a research
setting. These recommendations will be routinely reevaluated as knowledge of diagnostic and clinical utility
of clinical genome-wide sequencing improves. While the
document was developed to direct practice in Canada,
the applicability of the statement is broader and will be
of interest to clinicians and health jurisdictions
internationally.

INTRODUCTION
There are approximately 7000 individually rare
monogenic diseases that, as a group, affect 1 in 50
individuals1 and collectively contribute to signiﬁcant
morbidity, mortality and healthcare costs. Despite
extensive investigations to identify the speciﬁc cause
of a rare disease, the underlying aetiology remains
unidentiﬁed for many patients. The diagnostic
process employed by most medical geneticists in
Canada involves clinical assessment followed by
sequential laboratory testing. Recent advances, such
as chromosomal microarray analyses and multigene
panel DNA tests, have increased diagnostic yield,
but the diagnosis remains elusive for the majority of
patients in whom there is a presumed monogenic
aetiology.2
In recent years, the cost of DNA sequencing has
declined rapidly.3 Next-generation sequencing
(NGS) technologies have made it possible to interrogate a patient’s genome in a cost-effective and
efﬁcient manner.4 While genome-wide sequencing
in Canada has been performed on a research basis
for several years, clinical diagnostic services based
on these technologies are just now becoming available and are increasingly being requested. Ensuring
that patients with genetic disease have appropriate
access to these diagnostic tests has, therefore,
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DEFINITIONS
▸ Primary indication: The constellation of clinical features that
lead to diagnostic evaluation by genome-wide sequencing.
▸ Medically actionable: A ﬁnding that may impact patient management to improve outcome.
▸ Genetic heterogeneity: The occurrence of similar or identical
phenotypes as a result of disruption of different genes.
▸ Monogenic (Mendelian) condition: A genetic condition
resulting from altered function of a single gene/locus.
▸ Multifactorial inheritance: Non-monogenic inheritance of
speciﬁc traits that are determined by the combined action of
multiple genetic and environmental factors.
▸ NGS: Massively parallel sequencing technologies that
produce many hundreds of thousands or millions of reads
simultaneously.
▸ Multigene panel sequencing: For the purpose of this document, multigene panel sequencing will refer to the targeted
sequencing, primarily by NGS, of a selection of genes associated with a speciﬁc clinical presentation. Genes included in
panels typically have a depth of coverage sufﬁcient to minimise false negatives.
▸ Whole-genome sequencing (WGS): A process used to determine the sequence of most of the DNA content encompassing the entire genome of an individual.
▸ Whole-exome sequencing (WES): A process used to determine
the DNA sequence of most of the protein-encoding exons
found in the genome of an individual.
▸ Clinical genome-wide sequencing: A generic term for the
process used to determine the sequence of most, if not all,
clinically signiﬁcant genes and its associated interpretation,
including bioinformatic analysis and clinical genotype–
phenotype correlation. This approach would be undertaken
by an appropriately certiﬁed laboratory to address a clinical
question.
▸ Primary ﬁnding: Genetic variant(s) identiﬁed by genomewide sequencing that explain the primary indication for
testing.
▸ Incidental ﬁnding: Genetic variant(s) identiﬁed by genomewide sequencing unrelated to the primary indication for
testing.
432

CONSIDERATIONS
The shift to NGS technologies
Traditional genetic sequencing uses Sanger technology, which is
limited by cost and throughput to the investigation of only one
or a very small number of genes at any one time. The increased
throughput of NGS permits DNA sequencing to be used in
numerous ways within the clinic, to analyse, for example, one
particular gene in multiple individuals (generally for population
screening) or multiple genes at once in a panel format (eg, for a
speciﬁc disease indication). NGS can also be employed to
analyse several thousand genes with known clinical impact (eg,
all genes listed in OMIM associated with human disease), the
protein-coding portion of the entire genome (WES) or an individual’s genome in its entirety (WGS). These last three
approaches, referred to in this statement as clinical genome-wide
sequencing, include the sequencing of genes that are not relevant to a patient’s primary indication.
The obvious advantage of genome-wide sequencing
approaches is the potential to identify the genetic cause of a
disease more efﬁciently. Data are now accumulating that highlight the diagnostic utility of genome-wide sequencing in the
clinic. For example, a large clinical laboratory in the USA has
reported a diagnostic rate of approximately 25% with WES in a
cohort of >2000 patients with a range of phenotypes suggestive
of monogenic disease.5 6 Other large cohorts have shown that
this rate may increase to >30% with sequencing of both the
proband and parents at the same time (trio analysis),7 and even
further (to >40%) with careful selection of patients based on
their clinical presentation.8 In many of these cases, a substantial
amount of unrevealing genetic testing had been completed prior
to WES. One could speculate that the success rate might be signiﬁcantly higher if WES is initiated as a ﬁrst-line investigation.
Given the demonstrated diagnostic utility in this context, clinical
genome-wide sequencing is being used increasingly in the diagnostic evaluation of patients with suspected genetic disease.

Limitations of genome-wide sequencing approaches
Depending on the particular approach, clinical genome-wide
sequencing has certain technical limitations, the details of which
will not be addressed here but can be found elsewhere.9–11
These limitations can include incomplete coverage, which may
result in false negatives, as well as the current inability to reliably assess certain disease mechanisms such as variation in
repetitive elements (eg, trinucleotide repeat expansions) and
structural variants, particularly with WES and other targeted
clinical capture methods. With respect to reporting, there are
ongoing challenges with the curation of databases of presumed
pathogenic mutations.12 All of these limitations must be considered when this technology is used in the clinical setting.

Diagnostic utility of genome-wide sequencing
A review of the literature was performed to identify clinical
indications for which genome-wide sequencing is beneﬁcial.
Literature on both WES and WGS, published before
1 December 2013, was examined. It is important to note that
the majority of reported patients who had genome-wide sequencing (mostly WES) had their testing as part of a research study;
as such, not all studies can be translated to the clinical setting.
Publications in which single patients or small cohorts of patients
were examined with the primary purpose of novel gene discovery were excluded. Publications were reviewed in detail by a
minimum of two working group members (including
medical geneticists, clinical laboratory geneticists and genetic
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become important. This document addresses the clinical use of
genome-wide sequencing of germline DNA in the diagnosis of
monogenic disease in Canada, but does not address the use
of genome-wide sequencing in other medical contexts, such as
molecular investigation of cancer or for population screening of
healthy individuals. While the document was developed to
direct practice in Canada, the applicability of the statement is
not conﬁned to Canadian borders and will be of interest to clinicians and health jurisdictions internationally.
The Canadian College of Medical Geneticists (CCMG) is a
Canadian professional organisation comprised of clinically
trained medical and laboratory geneticists that establishes professional standards of clinical genetics practice across the
country. This Position Statement provides recommendations on
clinical genome-wide sequencing for those providing clinical
genetic services in Canada. The statement was developed by
two multidisciplinary working groups, one focusing on clinical
indications and one on incidental ﬁndings. It was posted on the
CCMG website on 14 January 2015 for comment by the membership and approved by the CCMG Board of Directors on 22
March 2015.

Clinical guidelines

Table 1 Factors that increase the likelihood of monogenic disease
and/or facilitate the interpretation of genome-wide data
Family history

Phenotype

Clinical
interpretation

Similarly affected individuals
Recognizable pattern of inheritance
Consanguinity
Severity of phenotype
Specificity of clinical presentation (eg, neuropathy,
metabolic disease)
Careful patient phenotyping (eg, detailed physical exam,
imaging, chemistry)
Normal chromosomal microarray analysis and other
relevant laboratory testing
Exclusion of acquired causes (eg, infection)

Boycott K, et al. J Med Genet 2015;52:431–437. doi:10.1136/jmedgenet-2015-103144

care in patients with multifactorial diseases such as myocardial
infarction.21 22 At the time of this review, there was a paucity of
literature supporting the use of genome-wide sequencing in the
prenatal setting.
When determining the underlying cause of a suspected
monogenic disease, there are a number of approaches that can
be undertaken, depending on the phenotypic presentation and
degree of genetic heterogeneity (ﬁgure 1). For example, in
genetic conditions with a characteristic clinical presentation
that is caused by disruption of one gene, or is associated with
a small degree of genetic heterogeneity (eg, CHARGE syndrome or tuberous sclerosis), analysis of the individual gene(s)
may be the ﬁrst-line approach. For moderately speciﬁc phenotypes with moderate genetic heterogeneity, the choice of
whether to use a multigene panel or clinical genome-wide
sequencing may depend on the clinical scenario and resources
available. For example, in patients being investigated because of
a family history of inherited arrhythmias, identiﬁcation of a
genetic mutation has important implications for patient management, and in this scenario, a cardiac-focused multigene
panel or a WES/WGS approach with comprehensive coverage
may be the optimal choice of testing. A clinical genome-wide
sequencing strategy accompanied by focused analysis of relevant genes may also be useful for conditions associated with a
speciﬁc phenotype and high genetic heterogeneity (eg, retinitis
pigmentosa) as it will allow the same approach to be used for
patients with a variety of clinical presentations, thereby facilitating diagnostic access for a broad community of patients. For
non-speciﬁc phenotypes (eg, moderate–severe intellectual disability) that are presumed to be monogenic and may have no
clear optimal set of genetic investigations beyond chromosomal
microarray, clinical genome-wide sequencing may also be indicated. For clinical presentations with low pre-test likelihood of
a monogenic aetiology such as familial late adult-onset ischaemic heart disease, clinical genome-wide sequencing is not
recommended.

Approaches to incidental ﬁndings

The issue of incidental ﬁndings as a challenge for diagnostic
testing has been the subject of a long running debate in the clinical genetics community. Clinical genome-wide sequencing will
generate data that are not related to the primary diagnostic question but may be useful in some clinical settings. The Incidental
Findings Working Group (SA, KB, JF, TH, BK, A-ML, JL, JM,
RM-L, TNN, JR, DLS, TS, ST, MZ) recognises that the clinical
utility of the majority of incidental ﬁndings has yet to be established23 and the magnitude of potential risks has not been empirically determined. In 2013, both the European Society of Human
Genetics (ESHG) and the American College of Medical Genetics
and Genomics (ACMG) published recommendations on how
incidental ﬁndings should be approached.24 25 The ESHG recommended that bioinformatic pipelines exclude genetic variants in
genes unrelated to the primary indication in order to minimise
discovery of incidental ﬁndings.24 They recommend that if an
unsolicited genetic variant is detected despite the initial ﬁltering
of the data and is indicative of a serious health problem, either in
the person tested or a close relative, health professionals should
report such variants. In contrast, the ACMG took a more prescriptive approach. Their original recommendations called for
the mandatory targeted analysis of a ‘minimum list’ of 56 genes
for 24 inherited disorders deemed to be clinically actionable for
any individual undergoing clinical genome-wide sequencing,
regardless of age or primary indication.25 The ACMG subsequently modiﬁed their recommendations to permit patients to
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counsellors) and discussed by the larger Clinical Indications
Working Group (CA, FB, KB, KC, BF, MG, TH, SH, SM, JLM,
BS, CvK). Each paper was assessed for its purpose, patient
cohort, methods used, diagnostic rate and conclusions. The publications were grouped into the following categories for review:
genetically heterogeneous diseases (eg, neuropathy, hearing loss,
mitochondrial disorders), unexplained clinical (including prenatal) presentations suspected to be monogenic (eg, multiple
congenital anomalies), common neurodevelopmental phenotypes (eg, autism, epilepsy, intellectual disability) and multifactorial diseases (eg, hypertension).
Overall, the Clinical Indications Working Group deﬁned
broad factors that increase the likelihood of identifying a
molecular cause for a patient’s disease using genome-wide
sequencing (table 1). It was recognised that a number of biases
exist within the literature, such as inclusion of patients with
highly speciﬁc phenotypes who had previously undergone uninformative genetic testing. In general, the factors listed in table 1
increase the chance that the cause of a disease phenotype is in
fact monogenic and might be identiﬁed using genome-wide
sequencing. These factors need to be considered when deciding
which patients are most appropriate to undergo this type of
clinical testing. In addition, several factors listed in table 1 facilitate the interpretation of genome-wide data in a clinical setting.
The disease presentations with the highest diagnostic yield
through genome-wide sequencing were monogenic conditions
associated with moderate to high genetic heterogeneity (ie, tens
to hundreds of alternative genes). For example, cerebellar ataxia
is a clinically and genetically heterogeneous condition that is a
feature of >100 rare diseases with onset in childhood. A retrospective study of 28 families of children with cerebellar ataxia
demonstrated a diagnostic success rate of 46% using WES,13
suggesting that WES or appropriately targeted clinical capture
methods are an effective tool in the diagnostic evaluation of this
particular set of patients. Similarly, there is literature to support
the role of genome-wide sequencing in various unexplained
clinical presentations.5 14 In the case of intellectual disability,
there is evidence for the diagnostic utility of genome-wide
sequencing in isolated cases when the patient is moderately–
severely affected or has a syndromic presentation.15–17 In contrast, at this time there is little evidence for the diagnostic utility
of genome-wide sequencing in patients with more complex
neurodevelopmental phenotypes, such as non-syndromic
autism.18 19 Nevertheless, clinical genome-wide sequencing
should be considered in individuals with an autism spectrum
disorder who have a comorbid intellectual disability and/or
other syndromic features.20 There is currently no evidence to
support the use of genome-wide sequencing to facilitate clinical

Clinical guidelines

opt out of receiving incidental ﬁndings from clinical genomewide sequencing.26 This modiﬁcation moved the opt-out discussion to the point of patient consent and sample submission,
rather than when results are received by the ordering clinician.
The ACMG recommendations permit laboratories to report or
not report other kinds of incidental ﬁndings, that is, those not
included in the medically actionable list, at their own discretion.
The publication of such statements and recommendations by
these international organisations prompted reﬂection on the
ethical issues around the reporting of incidental ﬁndings and
resulted in the development of a proposed set of considerations
for the Canadian context,27 which have been largely adopted
here.

The Canadian context
Canada’s publicly funded healthcare system, through the
Canada Health Act, provides universal coverage for medically
necessary healthcare services on the basis of need, rather than
the ability to pay. The majority of services are provided by physicians and other professionals who are paid on a fee-for-service
basis. This system is perhaps best described as an interlocking
set of 10 provincial and 3 territorial health insurance plans,
with the federal government providing partial funding to the
provinces and territories. Decisions regarding resource allocation, including availability of particular services within each
province and access to out-of-province genetic testing, are made
by the individual provinces and territories and differ across the
country. Thus, each province and territory needs to consider
how new testing technologies should be implemented. In addition, physicians practising within each province need to balance
their obligations to the individual patient with the use of ﬁnite
resources within the province when considering diagnostic
options. These recommendations provide an opportunity for
consistency in the approach to the use of clinical genome-wide
sequencing across the country despite provincial jurisdiction.

RECOMMENDATIONS
1. Recommendations for diagnostic assessment
1.1 Given the complexity of interpretation and counselling,
clinical genome-wide sequencing should only be
ordered by a clinical geneticist or other physician with
434

sufﬁcient expertise in use of the technology and clinical
interpretation of the results.
1.2 Clinical exome sequencing, at this time, should only be
used to interrogate the genome for nucleotide sequence
variants in genes known to cause disease. Clinical WGS
may be used to detect CNV and structural variation in
addition to sequence variants, though it is not currently
a ﬁrst-tier test for such analyses.
1.3 Clinical genome-wide sequencing should be considered
in the investigation of an affected individual when his/
her phenotype or family history suggests a monogenic
aetiology in whom the causal mutation(s) are unknown,
and one or more of the following additional conditions
apply:
▸ the phenotype is associated with a high degree of genetic
heterogeneity;
▸ speciﬁc genetic tests have failed to arrive at a diagnosis and
testing of other clinically relevant genes is appropriate;
▸ genome-wide sequencing is a more cost-effective approach
than available individual gene or gene panel testing.
1.4 Testing should always be done on the affected individual
and discussion held with the clinical laboratory to determine whether additional affected relatives or unaffected
parents should be analysed concurrently, if available.
1.5 Careful consideration of the issues and complexities
around clinical genome-wide sequencing should be
undertaken before its use prenatally, as limited evidence
currently exists supporting its use.
The Clinical Indications Working Group has developed a decision aid for the incorporation of genome-wide sequencing into
the diagnostic evaluation of patients with rare diseases
(ﬁgure 2). The most critical component of this process is clinical
phenotyping. This suggested framework is based on our current
understanding and will be re-evaluated over time as new data
become available. Ultimately, the ordering physician’s clinical
judgement should prevail.
2. Pre-test recommendations
2.1 Standard clinical assessment, including detailed phenotyping, should be undertaken prior to testing to facilitate interpretation of the genome-wide variants.
2.2 Prior to testing, genetic counselling for the patient/
family should be undertaken and documented in the
Boycott K, et al. J Med Genet 2015;52:431–437. doi:10.1136/jmedgenet-2015-103144
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Figure 1 A schematic indicating the
utility of different sequencing
approaches based on phenotype
speciﬁcity and genetic heterogeneity.
Each of these technologies has
strengths and weakness; genome-wide
sequencing provides broader coverage
in general but may have less coverage
of speciﬁc regions, and thus has a risk
of missing deleterious variants.
Genome-wide sequencing may be
considered for highly genetically
heterogeneous conditions or in
instances of undeﬁned clinical
syndromes suggestive of a genetic
aetiology. The clinician must weigh the
pros and cons of different approaches
that are available.

Clinical guidelines

medical record by a qualiﬁed individual with a thorough
understanding of clinical genome-wide sequencing. The
counselling should include:
▸ formal written informed consent obtained prior to testing;
▸ information regarding the limitations of the test methodology used, occurrence of variants of unknown or uncertain
signiﬁcance, and the possibility of incidental ﬁndings;
▸ discussion of expected outcomes and what will, and will not,
be reported from the test, including variant classes of both
primary ﬁndings and various kinds of incidental ﬁndings,
and the choices pertaining thereto;
▸ potential issues related to insurance and discrimination;
▸ possible (or deﬁnite) need for parental samples and additional testing, and information about what will, and will
not, be reported with respect to samples obtained from the
parents, or other unaffected family members;
▸ an explanation of what will happen with data, including how
long they will be stored, and if and when additional analysis
or re-analysis will be performed in the future.
2.3 All patients/families should be given the option of
having coded or anonymised genome-wide and phenotypic data deposited and stored in an international database to assist in interpretation of genome-wide studies
of themselves and other patients.
2.4 All patients/families should be given the opportunity to
enrol in current or future research studies to understand
the relationship of genome-wide variants found in them
and clinical abnormalities.
3. Recommendations for incidental ﬁndings
The CCMG recognises that the reporting of incidental ﬁndings is a controversial issue, due to the nature of the potential
risks and beneﬁts, coupled with a lack of empiric knowledge.
Consequently, until the beneﬁts of reporting incidental ﬁndings are established, the CCMG recommends a cautious
Boycott K, et al. J Med Genet 2015;52:431–437. doi:10.1136/jmedgenet-2015-103144

approach; we do not endorse the intentional clinical analysis
of disease genes unrelated to the primary indication, even if
the results might be medically actionable. Thus, to minimise
the discovery of incidental ﬁndings, bioinformatic analysis of
genome-wide sequencing may be performed using selective ﬁltering (in silico gene panels) that are highly speciﬁc to the
primary indication (ie, comparable to a multigene panel often
requested now for a speciﬁc clinical presentation). This will
minimise unanticipated and potentially high-cost (dollar or
emotional) impacts on the healthcare system, patients, and
their families, and will result in faster analysis for variants
that are relevant to the patient’s primary indication. However,
we recognise that some clinical laboratories may wish to offer
a broader genetic analysis that includes the assessment of
genes that may be associated with diseases unrelated to the
primary indication for testing. In this instance, the possibility
of identifying incidental ﬁndings exists, and should such a
ﬁnding be detected, then, in principle,
3.1 Competent adults should be given the option prior to
testing to receive (or not receive) incidental ﬁndings unrelated to the primary test indication. Adult patients should
be fully informed about what type of incidental ﬁndings
could occur with the speciﬁc test being considered, which
incidental ﬁndings will not be returned to them (eg, incidental variants of uncertain signiﬁcance or low-penetrance
genetic predispositions) and which incidental ﬁndings the
patient may have returned if s/he so chooses.
3.2 In children, incidental results that reveal risk for a highly
penetrant condition that is medically actionable during
childhood should be reported to the parents. A child’s risk
for adult-onset genetic conditions should not be communicated unless (1) the parents request such disclosure, AND
(2) disclosure of the information could prevent serious
harm to the health of a parent or family member, as
435
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Figure 2 Decision aid to facilitate the diagnostic evaluation of patients with rare disease of suspected monogenic aetiology. This decision aid
highlights where genome-wide sequencing may prove useful in the evaluation process. The conditions listed in each box are representative examples
only. For speciﬁc clinical presentations associated with genetic heterogeneity, the decision regarding the use of a targeted panel versus
genome-wide sequencing is dependent on a number of factors, including the availability of the testing options and the yield of such panels. Patients
with negative targeted gene panels may beneﬁt from subsequent clinical genome-wide sequencing. Conversely, consideration of a targeted panel
subsequent to uninformative clinical genome-wide sequencing would be dependent on the depth of coverage achieved in the latter instance.

Clinical guidelines
are generated. All Canadian jurisdictions need to discuss and
plan for the implementation of clinical genome-wide sequencing
in the near term. These recommendations may also prove useful
to other countries in the process of translating these technologies
to the care of patients with monogenic diseases.
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